Inflammasomes in neuroinflammation and changes in brain function: A focused review

Frontiers in Neuroscience

Volumn 8, Issue SEP, 2014, Pages 1-22

  Singhal, Gaurav ^a   Jaehne, Emily J ^a   Corrigan, Frances ^a   Toben, Catherine ^a   Baune, Bernhard T ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Aging; Alzheimer's disease; Cytokines; Depression; IL 1; Inflammasomes; Neuroinflammation; NLRP

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD14 ANTIGEN; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; INTERLEUKIN 6; LYMPHOTOXIN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; CASPASE 5; CYTOKINE; INTERLEUKIN 1BETA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR;

AGING; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR CHANGE; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; COGNITION; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HUMORAL IMMUNITY; HUNTINGTON CHOREA; MAJOR DEPRESSION; MEDLINE; METABOLIC DISORDER; MULTIPLE SCLEROSIS; NEOPLASM; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OBESITY; PARKINSON DISEASE; SYSTEMATIC REVIEW; BRAIN DISEASE; COGNITIVE DEFECT; COMPLEX FORMATION; DEGENERATIVE DISEASE; GENETIC PREDISPOSITION; INNATE IMMUNITY; MENTAL DISEASE; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

EID: 84907169998     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00315     Document Type: Article

References (165)

1. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Molecular cell (2002) 10(2):417-26. PubMed PMID: 12191486.
2. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases. Mol Neurodegener (2009) 4(47):1-13.
3. Walker A, Kavelaars A, Heijnen C, Dantzer R. Neuroinflammation and Comorbidity of Pain and Depression. Pharmacological reviews (2014) 66(1):80-101.
4. Pimplikar SW. Neuroinflammation in Alzheimer's Disease: from Pathogenesis to a Therapeutic Target. Journal of clinical immunology (2014):1-6.
5. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism & related disorders (2012) 18:S210-S2.
6. Möller T. Neuroinflammation in Huntington's disease. Journal of neural transmission (2010) 117(8):1001-8.
7. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. New England Journal of Medicine (2006) 354(9):942-55.
8. Biesmans S, Meert TF, Bouwknecht JA, Acton PD, Davoodi N, De Haes P, et al. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators of inflammation (2013) 2013.
9. Ownby RL. Neuroinflammation and cognitive aging. Current psychiatry reports (2010) 12(1):39-45.
10. Hein AM, O'Banion MK. Neuroinflammation and memory: the role of prostaglandins. Molecular neurobiology (2009) 40(1):15-32.
11. Sparkman NL, Johnson RW. Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. Neuroimmunomodulation (2008) 15(4-6):323-30.
12. Godbout J, Chen J, Abraham J, Richwine A, Berg B, Kelley K, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. The FASEB journal (2005) 19(10):1329-31.
13. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. Journal of neuroscience research (2010) 88(8):1615-31.
14. Arend WP, Palmer G, Gabay C. IL 1, IL 18, and IL 33 families of cytokines. Immunological reviews (2008) 223(1):20-38.
15. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annual review of immunology (2011) 29:707-35. doi: 10.1146/annurev-immunol-031210-101405. PubMed PMID: 21219188.
16. Cacquevel M, Lebeurrier N, Cheenne S, Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets (2004) 5(6):529-34.
17. Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Bührer C, Stahel PF. IL-18: a key player in neuroinflammation and neurodegeneration? Trends in neurosciences (2005) 28(9):487-93.
18. Godbout JP, Johnson RW. Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunology and allergy clinics of North America (2009) 29(2):321-37.
19. Tha KK, Okuma Y, Miyazaki H, Murayama T, Uehara T, Hatakeyama R, et al. Changes in expressions of proinflammatory cytokines IL-1β, TNF-a and IL-6 in the brain of senescence accelerated mouse (SAM) P8. Brain research (2000) 885(1):25-31.
20. Zhang Y, Liu L, Peng YL, Liu YZ, Wu TY, Shen XL, et al. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS neuroscience & therapeutics (2014) 20(2):119-24. doi: 10.1111/cns.12170. PubMed PMID: 24279434.
21. Mawhinney LJ, de Rivero Vaccari JP, Dale GA, Keane RW, Bramlett HM. Heightened inflammasome activation is linked to age-related cognitive impairment in Fischer 344 rats. BMC neuroscience (2011) 12(1):123.
22. Liu L, Chan C. The role of inflammasome in Alzheimer's disease. Ageing research reviews (2014). doi: 10.1016/j.arr.2013.12.007. PubMed PMID: 24561250.
23. Simi A, Lerouet D, Pinteaux E, Brough D. Mechanisms of regulation for interleukin- 1β in neurodegenerative disease. Neuropharmacology (2007) 52(8):1563-9.
24. Tan MS, Yu JT, Jiang T, Zhu XC, Tan L. The NLRP3 inflammasome in Alzheimer's disease. Molecular neurobiology (2013) 48(3):875-82. doi: 10.1007/s12035-013-8475-x. PubMed PMID: 23686772.
25. Cedillos RO. Alpha-Synuclein Aggregates Activate the Nlrp3 Inflammasome Following Vesicle Rupture. (2013).
26. Gris D, Ye Z, Iocca HA, Wen H, Craven RR, Gris P, et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. The Journal of Immunology (2010) 185(2):974-81.
27. Fischer A, Otte C, Krieger T, Nicholls RA, Krüger S, Ziegler KJ, et al. Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression. Psychoneuroendocrinology (2012) 37(10):1712-8.
28. Grant RW, Dixit VD. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Frontiers in immunology (2013) 4:50. doi: 10.3389/fimmu.2013.00050. PubMed PMID: 23483669; PubMed Central PMCID: PMC3592198.
29. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes (2013) 62(1):194-204. doi: 10.2337/db12-0420. PubMed PMID: 23086037; PubMed Central PMCID: PMC3526026.
30. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America (2011) 108(37):15324-9. doi: 10.1073/pnas.1100255108. PubMed PMID: 21876127; PubMed Central PMCID: PMC3174591.
31. Garg NJ. Inflammasomes in cardiovascular diseases. American journal of cardiovascular disease (2011) 1(3):244.
32. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nature immunology (2012) 13(4):343-51.
33. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine (2009) 151(4):264-9.
34. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of internal medicine (2009) 151(4):W-65-W-94.
35. Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. The Journal of clinical investigation (2009) 119(12):3502.
36. Inohara N, Chamaillard M, McDonald C, Nunez G. NOD-LRR proteins: role in hostmicrobial interactions and inflammatory disease. Annu Rev Biochem (2005) 74:355-83.
37. Kanneganti T-D, Lamkanfi M, Núñez G. Intracellular NOD-like receptors in host defense and disease. Immunity (2007) 27(4):549-59.
38. Franchi L, Warner N, Viani K, Nuñez G. Function of Nod like receptors in microbial recognition and host defense. Immunological reviews (2009) 227(1):106-28.
39. Petrilli V, Papin S, Tschopp J. The inflammasome. Current biology: CB (2005) 15(15):R581. doi: 10.1016/j.cub.2005.07.049. PubMed PMID: 16085473.
40. Cannon JG. Inflammatory cytokines in nonpathological states. Physiology (2000) 15(6):298-303.
41. Barksby H, Lea S, Preshaw P, Taylor J. The expanding family of interleukin 1 cytokines and their role in destructive inflammatory disorders. Clinical & Experimental Immunology (2007) 149(2):217-25.
42. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annual review of immunology (2009) 27:519-50.
43. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nature Reviews Immunology (2010) 10(2):89-102.
44. Dinarello CA. Proinflammatory cytokines. CHEST Journal (2000) 118(2):503-8.
45. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neuroscience and biobehavioral reviews (2009) 33(3):355-66. doi: 10.1016/j.neubiorev.2008.10.005. PubMed PMID: 18996146.
46. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, et al. Increased plasma levels of interleukin-1, interleukin-6 and a-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? Journal of neuroimmunology (2000) 103(1):97-102.
47. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull (2003) 61(3):255-60.
48. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nature Reviews Immunology (2010) 10(2):103-10.
49. Eyre H, Baune BT. Neuroimmunological effects of physical exercise in depression. Brain, behavior, and immunity (2012) 26(2):251-66. doi: 10.1016/j.bbi.2011.09.015. PubMed PMID: 21986304.
50. Rothwell NJ, Luheshi G, Toulmond S. Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. Pharmacology & therapeutics (1996) 69(2):85-95.
51. Hanisch UK. Microglia as a source and target of cytokines. Glia (2002) 40(2):140-55.
52. van der Staay FJ. Assessment of age-associated cognitive deficits in rats: a tricky business. Neuroscience & Biobehavioral Reviews (2002) 26(7):753-9.
53. Heneka MT, O'Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer's disease. Journal of neural transmission (2010) 117(8):919-47.
54. McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Annals of the New York Academy of Sciences (2004) 1035(1):104-16.
55. Godbout JP, Moreau M, Lestage J, Chen J, Sparkman NL, J OC, et al. Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology (2008) 33(10):2341-51. doi: 10.1038/sj.npp.1301649. PubMed PMID: 18075491; PubMed Central PMCID: PMC2907915.
56. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology (2007) 120(4):435-46.
57. Senchina DS, Kohut ML. Immunological outcomes of exercise in older adults. Clinical interventions in aging (2007) 2(1):3.
58. Shinkai S, Konishi M, Shephard RJ. Aging and immune response to exercise. Canadian journal of physiology and pharmacology (1998) 76(5):562-72. PubMed PMID: 9839083.
59. Huang Y, Henry C, Dantzer R, Johnson R, Godbout J. Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. Neurobiology of aging (2008) 29(11):1744-53.
60. Mrak RE, Griffin WST. Glia and their cytokines in progression of neurodegeneration. Neurobiology of aging (2005) 26(3):349-54.
61. Dilger RN, Johnson RW. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. Journal of leukocyte biology (2008) 84(4):932-9. doi: 10.1189/jlb.0208108. PubMed PMID: 18495785; PubMed Central PMCID: PMC2538600.
62. Sugaya K, Chouinard M, Greene R, Robbins M, Personett D, Kent C, et al. Molecular indices of neuronal and glial plasticity in the hippocampal formation in a rodent model of age-induced spatial learning impairment. The Journal of neuroscience (1996) 16(10):3427-43.
63. Rozovsky I, Finch C, Morgan T. Age-related activation of microglia and astrocytes: in vitro studies show persistent phenotypes of aging, increased proliferation, and resistance to down-regulation. Neurobiology of aging (1998) 19(1):97-103.
64. Conde JR, Streit WJ. Microglia in the aging brain. Journal of Neuropathology & Experimental Neurology (2006) 65(3):199-203.
65. Streit WJ. Microglia and neuroprotection: implications for Alzheimer's disease. Brain research reviews (2005) 48(2):234-9.
66. Dong Y, Benveniste EN. Immune function of astrocytes. Glia (2001) 36(2):180-90.
67. Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. Journal of neuroi nflammation (2012) 9:179.
68. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochemical and biophysical research communications (2009) 388(4):621-5.
69. van de Veerdonk FL, Netea MG. Toll-Like Receptors and Inflammasomes. The Inflammasomes. Springer (2011). p. 123-32.
70. Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cellular and Molecular Life Sciences (2012) 69(18):2999-3013.
71. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer's disease: amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors. Progress in neurobiology (2009) 87(3):181-94.
72. Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nature Reviews Immunology (2010) 10(3):210-5.
73. Belmaker R, Agam G. Major depressive disorder. New England Journal of Medicine (2008) 358(1):55-68.
74. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology (2011) 36(12):2452-9.
75. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A metaanalysis of cytokines in major depression. Biological psychiatry (2010) 67(5):446-57.
76. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic medicine (2009) 71(2):171-86.
77. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine (1997) 9(11):853-8.
78. Farooq RK, Isingrini E, Tanti A, Le Guisquet A-M, Arlicot N, Minier F, et al. Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation? Behavioural brain research (2012) 231(1):130-7.
79. Alcocer-Gómez E, de Miguel M, Casas-Barquero N, Núñez-Vasco J, Sánchez- Alcazar JA, Fernández-Rodríguez A, et al. NLRP3 inflammasome is activated in mononuclear blood cells. (2013).
80. Hohmann H, Bechter K, Schneider E. A small and validated cytokine panel supports inflammasome activation in cerebrospinal fluid of patients with major depression and schizophrenia. Neurology, Psychiatry and Brain Research (2014) 20(1):13-4.
81. Moon M, McCusker R, Lawson M, Dantzer R, Kelley K. Mice lacking the inflammasome component caspase-1 are resistant to central lipopolysaccharide-induced depressive-like behavior. Brain, behavior, and immunity (2009) 23:S50.
82. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain, behavior, and immunity (2013) 31:105-14. doi: 10.1016/j.bbi.2012.12.008. PubMed PMID: 23261775.
83. Younger/Early Onset Alzheimer's & Dementia: Alzheimer's association [cited 2014 13 May]. Available from: http://www.alz.org/alzheimers_disease_early_onset.asp.
84. Kim J, Ahn H, Han BC, Lee SH, Cho YW, Kim CH, et al. Korean red ginseng extracts inhibit NLRP3 and AIM2 inflammasome activation. Immunology letters (2014) 158(1-2):143-50. doi: 10.1016/j.imlet.2013.12.017. PubMed PMID: 24418475.
85. Kamboh M, Demirci F, Wang X, Minster R, Carrasquillo M, Pankratz V, et al. Genome-wide association study of Alzheimer's disease. Translational psychiatry (2012) 2(5):e117.
86. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer's disease. Human molecular genetics (2009) 18(R2):R137-R45.
87. Babic T. The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery & Psychiatry (1999) 67(4):558-.
88. Palop JJ, Mucke L. Amyloid-[beta]-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nature neuroscience (2010) 13(7):812-8.
89. Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience (2007) 8(9):663-72.
90. Agostinho P, A Cunha R, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Current pharmaceutical design (2010) 16(25):2766-78.
91. Wenk GL. Neuropathologic changes in Alzheimer's disease. Journal of Clinical Psychiatry (2003) 64:7-10.
92. Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age and ageing (2006) 35(4):336-8.
93. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of neurology (2008) 65(11):1509-17.
94. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiological reviews (2004) 84(2):361-84.
95. Lee H-g, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends in molecular medicine (2005) 11(4):164-9.
96. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. The Scientific World Journal (2012) 2012.
97. Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernández J, Campos- Peña V. Inflammatory process in Alzheimer's Disease. Frontiers in integrative neuroscience (2013) 7.
98. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of betaamyloid generation. Journal of neuroinflammation (2008) 5(1):37.
99. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice. Neurobiology of disease (2003) 14(1):133-45.
100. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharideinduced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. The Journal of neuroscience (2005) 25(39):8843-53.
101. Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. The FASEB Journal (2011) 25(1):5-13.
102. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nature immunology (2008) 9(8):857-65.
103. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death & Differentiation (2007) 14(9):1583-9.
104. Hattori N, Kitagawa K, Higashida T, Yagyu K, Shimohama S, Wataya T, et al. Cl-- ATPase and Na+/K+-ATPase activities in Alzheimer's disease brains. Neuroscience letters (1998) 254(3):141-4.
105. Perregaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. Journal of Biological Chemistry (1994) 269(21):15195-203.
106. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, et al. Altered Cytokine Production in Mice Lacking P2X7Receptors. Journal of Biological Chemistry (2001) 276(1):125-32.
107. Burnstock G. Introduction to purinergic signalling in the brain. Glioma Signaling. Springer (2013). p. 1-12.
108. Rubartelli A. DAMP-mediated activation of NLRP3-inflammasome in brain sterile inflammation: the fine line between healing and neurodegeneration. Frontiers in immunology (2014) 5.
109. Masters SL, O'Neill LA. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends in molecular medicine (2011) 17(5):276-82.
110. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biology and Medicine (1997) 23(1):134-47.
111. Martinon F. Signaling by ROS drives inflammasome activation. European journal of immunology (2010) 40(3):616-9.
112. Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. The Journal of experimental medicine (2011) 208(3):417-20.
113. Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nature reviews Immunology (2010) 10(3):210-5. doi: 10.1038/nri2725. PubMed PMID: 20168318.
114. Brothers HM, Bardou I, Hopp SC, Marchalant Y, Kaercher RM, Turner SM, et al. Time-Dependent Compensatory Responses to Chronic Neuroinflammation in Hippocampus and Brainstem: The Potential Role of Glutamate Neurotransmission. Journal of Alzheimers Disease & Parkinsonism (2013).
115. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nature Reviews Immunology (2005) 5(8):629-40.
116. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). The FASEB Journal (1990) 4(11):2860-7.
117. Ikejima T, Okusawa S, Ghezzi P, Van Der Meer JW, Dinarello CA. Interleukin-l Induces Tumor Necrosis Factor (TNF) in Human Peripheral Blood Mononuclear Cells In Vitro and a Circulating TNF-Iike Activity in Rabbits. Journal of Infectious Diseases (1990) 162(1):215-23.
118. Knofler M, Kiss H, Mosl B, Egarter C, Husslein P. Interleukin-1 stimulates tumor necrosis factor-alpha (TNF-alpha) release from cytotrophoblastic BeWo cells independently of induction of the TNF-alpha mRNA. FEBS letters (1997) 405(2):213-8. Epub 1997/03/24. PubMed PMID: 9089293.
119. Alvarez S, Munoz-Fernandez MA. TNF-Alpha may mediate inflammasome activation in the absence of bacterial infection in more than one way. PloS one (2013) 8(8):e71477. doi: 10.1371/journal.pone.0071477. PubMed PMID: 23940760; PubMed Central PMCID: PMC3737100.
120. Taniguchi K, Yamamoto S, Hitomi E, Inada Y, Suyama Y, Sugioka T, et al. Interleukin-33 is induced by tumor necrosis factor-alpha and interferon-gamma in keratinocytes, and contributes to allergic contact dermatitis. J Investig Allergol Clin Immunol (2013) 23(6):428-34.
121. Koutoulaki A, Langley M, Sloan AJ, Aeschlimann D, Wei X-Q. TNFa and TGF-β1 influence IL-18-induced IFN? production through regulation of IL-18 receptor and T-bet expression. Cytokine (2010) 49(2):177-84.
122. Chandrasekar B, Colston JT, de la Rosa SD, Rao PP, Freeman GL. TNF-alpha and H2O2 induce IL-18 and IL-18R beta expression in cardiomyocytes via NF-kappa B activation. Biochemical and biophysical research communications (2003) 303(4):1152-8. Epub 2003/04/10. PubMed PMID: 12684057.
123. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 34(2):213-23. doi: 10.1016/j.immuni.2011.02.006. PubMed PMID: 21349431.
124. McGeough MD, Pena CA, Mueller JL, Pociask DA, Broderick L, Hoffman HM, et al. Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasomemediated mouse models. Journal of immunology (2012) 189(6):2707-11. doi: 10.4049/jimmunol.1101737. PubMed PMID: 22904305; PubMed Central PMCID: PMC3495128.
125. Baune BT, Konrad C, Grotegerd D, Suslow T, Ohrmann P, Bauer J, et al. Tumor necrosis factor gene variation predicts hippocampus volume in healthy individuals. Biological psychiatry (2012) 72(8):655-62.
126. Eyre H, Papps E, Baune BT. Treating depression and depression-like behavior with physical activity: an immune perspective. Frontiers in psychiatry (2013) 4.
127. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain research (1989) 491(2):394-7.
128. Schwarz MJ, Chiang S, Müller N, Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain, behavior, and immunity (2001) 15(4):340-70.
129. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annual review of immunology (2002) 20(1):55-72.
130. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. (1994).
131. Du Clos TW. Function of C-reactive protein. Annals of medicine (2000) 32(4):274-8.
132. Padilla AM, Perez W. Acculturation, social identity, and social cognition: A new perspective. Hispanic Journal of Behavioral Sciences (2003) 25(1):35-55.
133. Kuo H-K, Yen C-J, Chang C-H, Kuo C-K, Chen J-H, Sorond F. Relation of Creactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. The Lancet Neurology (2005) 4(6):371-80.
134. McGeer PL, McGeer E, Yasojima K. Alzheimer disease and neuroinflammation. Advances in Dementia Research. Springer (2000). p. 53-7.
135. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain research reviews (1995) 21(2):195-218.
136. Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer's disease brain. The American journal of pathology (1999) 154(3):927-36.
137. Janeway CA, Travers P, Walport M, Shlomchik MJ. The complement system and innate immunity. (2001).
138. Mélik-Parsadaniantz S, Rostène W. Chemokines and neuromodulation. Journal of neuroi mmunology (2008) 198(1):62-8.
139. Proost P, Wuyts A, Van Damme J. The role of chemokines in inflammation. International Journal of Clinical and Laboratory Research (1996) 26(4):211-23.
140. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiology of disease (2010) 37(3):510-8.
141. Campbell A. Inflammation, neurodegenerative diseases, and environmental exposures. Annals of the New York Academy of Sciences (2004) 1035(1):117-32.
142. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. Journal of applied physiology (2005) 98(4):1154-62.
143. Petersen AMW, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. Journal of physiology and pharmacology (2006) 57(10):43-51.
144. Poli A, Kmiecik J, Domingues O, Hentges F, Bléry M, Chekenya M, et al. NK Cells in Central Nervous System Disorders. The Journal of Immunology (2013) 190(11):5355-62.
145. von Büdingen H-C, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, et al. B cell exchange across the blood-brain barrier in multiple sclerosis. The Journal of clinical investigation (2012) 122(12):4533.
146. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends in pharmacological sciences (2006) 27(1):48-55.
147. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death & Differentiation (2006) 14(1):10-22.
148. Schroder K, Tschopp J. The inflammasomes. Cell (2010) 140(6):821-32.
149. Morimoto K, Murasugi T, Oda T. Acute Neuroinflammation Exacerbates Excitotoxicity in Rat Hippocampus in Vivo. Experimental neurology (2002) 177(1):95-104.
150. Wager-Smith K, Markou A. Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neuroscience & Biobehavioral Reviews (2011) 35(3):742-64.
151. Hauss-Wegrzyniak B, Dobrzanski P, Stoehr JD, Wenk GL. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain research (1998) 780(2):294-303.
152. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain: a journal of neurology (2009) 132(5):1175-89.
153. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant a-synuclein linked to early-onset Parkinson disease. Nature medicine (1998) 4(11):1318-20.
154. Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from a-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry (2000) 39(10):2552-63.
155. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiology Biomarkers & Prevention (2005) 14(10):2413-8.
156. De Rekeneire N, Peila R, Ding J, Colbert LH, Visser M, Shorr RI, et al. Diabetes, Hyperglycemia, and Inflammation in Older Individuals The Health, Aging and Body Composition study. Diabetes care (2006) 29(8):1902-8.
157. Stannus OP, Jones G, Blizzard L, Cicuttini FM, Ding C. Associations between serum levels of inflammatory markers and change in knee pain over 5 years in older adults: a prospective cohort study. Annals of the rheumatic diseases (2013) 72(4):535-40.
158. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women the women's health and aging study. Circulation (2001) 103(7):947-53.
159. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacology & therapeutics (2011) 130(2):226-38.
160. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. The Journal of Neuroscience (2005) 25(40):9275-84.
161. Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. The International Journal of Neuropsychopharmacology (2002) 5(04):389-99.
162. Connat JL. Inflammasome and cardiovascular diseases. Annales de cardiologie et d'angeiologie (2011) 60(1):48-54. doi: 10.1016/j.ancard.2010.07.011. PubMed PMID: 20800829.
163. Fallowfield L, Ratcliffe D, Jenkins V, Saul J. Psychiatric morbidity and its recognition by doctors in patients with cancer. British journal of cancer (2001) 84(8):1011.
164. Organization WH. The top 10 causes of death: World Health Organization (2014) [updated May 2014; cited 2014 5 June]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.
165. Wilson SP, Cassel SL. Inflammasome-mediated autoinflammatory disorders. Postgraduate medicine (2010) 122(5):125-33. doi: 10.3810/pgm.2010.09.2209. PubMed PMID: 20861596; PubMed Central PMCID: PMC3648991.